These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 30460702)

  • 1. Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials.
    Cardoso R; Willems S; Gerstenfeld EP; Verma A; Schilling R; Hohnloser SH; Okumura K; Nordaby M; Brouwer MA; Calkins H
    Clin Cardiol; 2019 Jan; 42(1):198-205. PubMed ID: 30460702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis.
    Ge Z; Faggioni M; Baber U; Sartori S; Sorrentino S; Farhan S; Chandrasekhar J; Vogel B; Qadeer A; Halperin J; Reddy V; Dukkipati S; Dangas G; Mehran R
    Cardiovasc Ther; 2018 Oct; 36(5):e12457. PubMed ID: 29971964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation.
    Cardoso R; Knijnik L; Bhonsale A; Miller J; Nasi G; Rivera M; Blumer V; Calkins H
    Heart Rhythm; 2018 Jan; 15(1):107-115. PubMed ID: 28917562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
    Wu S; Yang YM; Zhu J; Wan HB; Wang J; Zhang H; Shao XH
    Am J Cardiol; 2016 Mar; 117(6):926-34. PubMed ID: 26803384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation.
    Zhao Y; Lu Y; Qin Y
    Int J Cardiol; 2018 Nov; 270():167-171. PubMed ID: 29903520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation: A Meta-analysis.
    Nairooz R; Ayoub K; Sardar P; Payne J; Almomani A; Pothineni NV; Shailesh F; Aronow WS; Mukherjee D
    Can J Cardiol; 2016 Jun; 32(6):814-23. PubMed ID: 26810476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation.
    Gunawardene M; Willems S; Schäffer B; Moser J; Akbulak RÖ; Jularic M; Eickholt C; Nührich J; Meyer C; Kuklik P; Sehner S; Czerner V; Hoffmann BA
    Clin Res Cardiol; 2017 Jan; 106(1):38-48. PubMed ID: 27435077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis.
    Santarpia G; De Rosa S; Polimeni A; Giampà S; Micieli M; Curcio A; Indolfi C
    PLoS One; 2015; 10(5):e0126512. PubMed ID: 25974377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation: Understanding the Gaps in Evidence.
    Martin AC; Godier A; Narayanan K; Smadja DM; Marijon E
    Circulation; 2018 Aug; 138(6):627-633. PubMed ID: 30354610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interrupted or Uninterrupted Oral Anticoagulants in Patients Undergoing Atrial Fibrillation Ablation.
    Yang P; Wang C; Ye Y; Huang T; Yang S; Shen W; Xu G; Wu Q
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):371-381. PubMed ID: 32232617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
    Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
    BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-Analysis of Safety and Efficacy of Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus Vitamin K Antagonists for Catheter Ablation of Atrial Fibrillation.
    Elgendy AY; Mahtta D; Barakat AF; Abuzaid A; Mahmoud A; Mentias A; Mahmoud AN; Elgendy IY
    Am J Cardiol; 2017 Nov; 120(10):1830-1836. PubMed ID: 28882334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimally interrupted novel oral anticoagulant versus uninterrupted vitamin K antagonist during atrial fibrillation ablation.
    De Heide J; Vroegh CJ; Bhagwandien RE; Wijchers SA; Szili-Torok T; Zijlstra F; Lenzen MJ; Yap SC
    J Interv Card Electrophysiol; 2018 Dec; 53(3):341-346. PubMed ID: 30074120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
    Yu HT; Shim J; Park J; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Kim YH; Pak HN
    Eur Heart J; 2019 May; 40(19):1531-1537. PubMed ID: 30590600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis.
    Ha FJ; Barra S; Brown AJ; Begley DA; Grace AA; Agarwal S
    Int J Cardiol; 2018 Jul; 262():51-56. PubMed ID: 29606512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant Benefit of Uninterrupted DOACs Versus VKA During Catheter Ablation of Atrial Fibrillation.
    Romero J; Cerrud-Rodriguez RC; Alviz I; Diaz JC; Rodriguez D; Arshad S; Cerna L; Taveras J; Grupposo V; Natale A; Garcia M; Di Biase L
    JACC Clin Electrophysiol; 2019 Dec; 5(12):1396-1405. PubMed ID: 31857038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies.
    Brunetti ND; Tricarico L; Tilz RR; Heeger CH; De Gennaro L; Correale M; Ieva R; Di Biase M; Rillig A; Metzner A; Santoro F
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):209-214. PubMed ID: 32080786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation.
    Trujillo TC; Dobesh PP; Crossley GH; Finks SW
    Pharmacotherapy; 2019 Jan; 39(1):94-108. PubMed ID: 30548542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.